Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
July 23, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs...
July 08, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
June 09, 2025 08:00 ET | Source: Humacyte, Inc

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
June 02, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
May 19, 2025 16:05 ET | Source: Humacyte, Inc

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
May 13, 2025 07:30 ET | Source: Humacyte, Inc

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter...
May 09, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
March 28, 2025 07:30 ET | Source: Humacyte, Inc

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first...
March 26, 2025 08:00 ET | Source: Humacyte, Inc

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...